^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Esophageal Cancer
    Drug:Jemperli (dostarlimab-gxly) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/21/2021
    Excerpt:
    Esophageal and Esophagogastric Junction Cancers...Dostarlimab-gxly...for MSI-H or dMMR tumors
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Solid Tumor)
    New
    Excerpt:
    JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced...solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GI 2021
    Title:

    Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.

    Published date:
    01/11/2021
    Excerpt:
    Of the 106 pts, 99 (93.4%) had GI tumors. Confirmed ORR in dMMR pts was 38.7% (95% CI: 29.4, 48.6), with a complete response rate of 7.5%. ORR was consistent across tumor type (Table). Dostarlimab demonstrated durable antitumor activity in a cohort of dMMR solid tumor pts, the majority of whom had GI cancers.
    Trial ID:
    GARNET